Nyxoah SA Ordinary Shares (NYXH) is a publicly traded Healthcare sector company. As of May 21, 2026, NYXH trades at $2.88 with a market cap of $127.49M and a P/E ratio of 0.00. NYXH moved +0.00% today. Year to date, NYXH is -39.15%; over the trailing twelve months it is -62.86%. Its 52-week range spans $2.72 to $11.87. Analyst consensus is buy with an average price target of $7.96. Rallies surfaces NYXH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Nyxoah Posts 25% U.S. Revenue Growth, €25.9M Cash and €36–40M Guidance: Nyxoah reported Q1 2026 net revenue of €6.4 million, up 13% sequentially globally and 25% in the U.S., driven by a strong Genio launch. The company ended the quarter with €25.9 million in cash and expects €36–40 million in full-year net revenue with 60–62% gross margin.
| Metric | Value |
|---|---|
| Price | $2.88 |
| Market Cap | $127.49M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.87 |
| 52-Week Low | $2.72 |
| Volume | 130 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
6 analysts cover NYXH: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.96.